NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates
SAN FRANCISCO, Jan. 3, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced a collaboration with Sanofi Pasteur -- the largest company entirely...
Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies
SAN FRANCISCO, Dec. 18, 2012 - Sutro Biopharma today announced a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody....
Sutro Biopharma Expands Senior Management Team Jeremy Bender, Ph.D., Joins as Chief Business Officer; Aaron K. Sato, Ph.D., Named Vice President, Research
SAN FRANCISCO, October 24, 2012 - Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, today announced the expansion of its senior...
Sutro Closes $16.5 Million Second Tranche of Series C Financing
SAN FRANCISCO, May 8, 2012 - Sutro Biopharma today announced the closing of the $16.5 million second tranche of its Series C financing. This financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta...
Sutro Announces Newly Formed Scientific Advisory Board Renowned Researchers James A. Wells, Ph.D., and James R. Swartz, Sc.D., to Guide Sutro’s Advancing Therapeutic Pipeline
SAN FRANCISCO, Jan. 7, 2012 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed James A. Wells, Ph.D., and James R. Swartz, Sc.D., to its...
Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
SAN FRANCISCO, Oct. 17, 2011 - Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., to Highlight Company's Technology Platform for the Highly Specific Design and Manufacturing of Novel Protein Therapeutics Sutro Biopharma, a biopharmaceutical company developing...
Study Shows Sutro Biopharma’s Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals Results Published in Biotechnology and Bioengineering Demonstrate that Cell-Free Production of a Biologically Active Human Cytokine Can be Scaled-up to Commercial Manufacturing Levels Study Featured in Journal’s Spotlight Section.
SAN FRANCISCO, May 19, 2011 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that a study published in the July issue of Biotechnology and...
Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics. Company’s First Major Collaboration Validates Potential of Biochemical Protein Synthesis Technology Platform.
San Francisco, CA Jan. 7, 2011 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for...
Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer Appointment Reflects Biopharmaceutical Company’s Commitment to the Development of Novel and Biosuperior Protein Therapeutics
San Francisco, CA Dec. 8, 2010 - Sutro Biopharma, a biopharmaceutical company developing both novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed Trevor Hallam, Ph.D., as chief scientific officer...
Sutro Biopharma Secures $36.5 Million in Series C Financing
South San Francisco, CA Nov. 17, 2010 - Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will support the company's ongoing development of novel biotherapeutics with superior pharmaceutical properties and...